SEROQUEL XR Indications at a Glance

SEROQUEL XR (quetiapine fumarate) in major depressive
disorder (MDD)

SEROQUEL XR is indicated in adults for use as adjunctive antidepressant therapy
to other antidepressants for patients with MDD.1

Most Common Adverse Reactions for SEROQUEL XR in
MDD

  • In the 6-week, placebo-controlled, fixed-dose adjunctive therapy clinical trials for major depressive disorder, the most commonly observed adverse reactions associated with the use of SEROQUEL XR (quetiapine fumarate) (incidence of 5% or greater and observed at a rate in SEROQUEL XR at least twice that of placebo) were somnolence* (150 mg: 37%; 300 mg: 43%), dry mouth (150 mg: 27%; 300 mg: 40%), fatigue (150 mg: 14%; 300 mg: 11%), constipation (300 mg only: 11%), and weight gain (300 mg only: 5%)1
  • In adjunctive therapy clinical trials in patients with MDD, 12.1% of patients on SEROQUEL XR discontinued due to adverse reactions, compared to 1.9% on placebo1
  • Somnolence* was the only adverse reaction leading to discontinuation that occurred at an incidence of ≥2% with SEROQUEL XR in adjunctive MDD trials (4.8% for SEROQUEL XR 150 mg/day, 8.0% for SEROQUEL XR 300 mg/day, and 0.3% for placebo)1,2

*Somnolence combines adverse reaction terms “somnolence” and “sedation.”

Efficacy Data in MDD

SEROQUEL XR (quetiapine fumarate) is proven effective in MDD as add-on therapy compared to antidepressant (AD) alone.1

Efficacy was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant treatment.1

For adult patients with an inadequate response after at least 6 weeks of treatment with an antidepressant.

In studies of SEROQUEL XR as adjunctive therapy in the treatment of MDD, patients were treated with one of the following antidepressants prior to study entry: Paxil® (paroxetine), Prozac® (fluoxetine), Zoloft® (sertraline), Lexapro® (escitalopram), Celexa® (citalopram), Cymbalta® (duloxetine), Effexor® (venlafaxine), amitryptiline, and Wellbutrin® (buproprion).1

All brand names and product names are trademarks of their respective owners.

SEROQUEL XR Dosing and Administration for MDD

Related information you may find helpful

Indications

SEROQUEL XR is indicated in adults for (1) adjunctive therapy to antidepressants in major depressive disorder; (2) acute depressive episodes in bipolar disorder; (3) acute manic or mixed episodes in bipolar I disorder, as either monotherapy or adjunct therapy to lithium or divalproex; (4) maintenance treatment of bipolar I disorder as an adjunct to lithium or divalproex; and (5) schizophrenia. SEROQUEL is indicated in adults for the treatment of (1) acute depressive episodes in bipolar disorder; (2) acute manic episodes in bipolar I disorder, as either monotherapy or adjunct therapy to lithium or divalproex; (3) maintenance treatment of bipolar I disorder as an adjunct to lithium or divalproex, and (4) schizophrenia. Patients should be periodically reassessed to determine the need for treatment and the appropriate dose.

Important Safety Information About SEROQUEL XR and SEROQUEL

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SEROQUEL XR and SEROQUEL are not approved for the treatment of patients with dementia-related psychosis.

Suicidal Thoughts and Behavior: Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. SEROQUEL XR and SEROQUEL are not approved for use in pediatric patients under ten years of age.

Contraindication: Hypersensitivity to quetiapine or to any excipients in the SEROQUEL XR or SEROQUEL formulation. Anaphylactic reactions have been reported in patients treated with SEROQUEL XR and SEROQUEL.

Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis:
In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared to placebo-treated subjects. SEROQUEL XR and SEROQUEL are not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): A potentially fatal symptom complex, sometimes referred to as NMS, has been reported in association with administration of antipsychotic drugs, including quetiapine. Rare cases of NMS have been reported with quetiapine. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment, and medical monitoring, and treatment of any concomitant serious medical problems.

Metabolic Changes:
Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain. In some patients, a worsening of more than one of the metabolic parameters of weight, blood glucose, and lipids was observed in clinical studies. Changes in these metabolic profiles should be managed as clinically appropriate.

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics, including quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse reactions in patients treated with atypical antipsychotics. Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations in lipids have been observed with quetiapine use. Increases in total cholesterol, LDL-cholesterol and triglycerides, and decreases in HDL-cholesterol have been reported in clinical trials. Appropriate clinical monitoring is recommended, including fasting blood lipid testing at the beginning of and periodically during treatment.

Weight Gain: Increases in weight have been observed in clinical trials. Patients receiving quetiapine should receive regular monitoring of weight.

Tardive Dyskinesia (TD): TD, a potentially irreversible syndrome of involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and total cumulative dose of antipsychotic drugs administered to the patient increase. Although much less commonly, TD can develop after relatively brief treatment periods at low doses or even after treatment discontinuation. TD may remit, partially or completely, if antipsychotic treatment is withdrawn. Quetiapine should be prescribed in a manner that is most likely to minimize the occurrence of TD, and discontinuation should be considered if signs and symptoms of TD occur.

Hypotension:  Quetiapine may induce orthostatic hypotension with associated dizziness, tachycardia, and syncope, especially during the initial dose titration period and should be used with caution in patients predisposed to hypotension or with known cardiovascular or cerebrovascular disease.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia, neutropenia, and agranulocytosis (including fatal cases), have been reported temporally related to atypical antipsychotics, including quetiapine. Patients with a pre-existing low white blood cell (WBC) count or a history of drug-induced leukopenia/neutropenia should have their complete blood count monitored frequently during the first few months of therapy. In these patients, quetiapine should be discontinued at the first sign of a decline in WBC absent other causative factors. Patients with neutropenia should be carefully monitored, and quetiapine should be discontinued in any patient if the absolute neutrophil count is <1000/mm3.

Cataracts: Examination of the lens by methods adequate to detect cataract formation, such as slit lamp exam or other appropriately sensitive methods, is recommended at initiation of treatment or shortly thereafter, and at 6-month intervals during chronic treatment.

QT Prolongation: Postmarketing cases show increases in QT interval in patients who overdosed on quetiapine, in patients with concomitant illness, and in patients taking medicines known to cause electrolyte imbalance or increase the QT interval. Avoid use with drugs that increase the QT interval and in patients with risk factors for prolonged QT interval.

Seizures: Quetiapine should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold (eg, Alzheimer’s dementia).

Potential for Cognitive and Motor Impairment: Since quetiapine has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle or operating hazardous machinery, until they are reasonably certain that quetiapine therapy does not affect them adversely.

Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotics. Appropriate care is advised for patients who may exercise strenuously, be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or be subject to dehydration.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Use caution in patients at risk for aspiration pneumonia. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia.

Warnings and Precautions Also Include: The risk of hypothyroidism, hyperprolactinemia, and discontinuation syndrome.

Common Adverse Reactions: The most commonly observed adverse reactions (incidence ≥5% and twice placebo) associated with the use of SEROQUEL XR versus placebo in clinical trials for all indications were somnolence (25%-52% vs 9%-13%), dry mouth (12%-40% vs 1%-8%), constipation (6%-11% vs 3%-6%), dizziness (10%-13% vs 4%-11%), increased appetite (2%-12% vs 0%-6%), dyspepsia (2%-7% vs 1%-4%), weight gain (3%-7% vs 0%-1%), fatigue (3%-14% vs 2%-4%), dysarthria (2%-5% vs 0%), and nasal congestion (2%-5% vs 1%). The most commonly reported adverse reactions associated with the use of SEROQUEL vs placebo in adults in clinical trials for all indications were somnolence (18%- 57% vs 8%-15%), dry mouth (9%-44% vs 3%-13%), dizziness (9%-18% vs 5%-7%), constipation (8%-10% vs 3%-5%), asthenia (2%-10% vs 1%-4%), abdominal pain (4%-7% vs 1%-3%), postural hypotension (4%-7% vs 1%-3%), pharyngitis (4%-6% vs 3%), weight gain (4%-6% vs 1%-3%), lethargy (5% vs 2%), ALT increased (5% vs 1%) and dyspepsia (4%-7%vs 1%-4%).

Please see Full Prescribing Information for SEROQUEL XR and SEROQUEL , including Boxed Warnings.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

REFERENCES:

  • 1. SEROQUEL XR Prescribing Information.
  • 2. Data on file, 272709, AstraZeneca Pharmaceuticals LP.

Log In

Close
 
 
 
Remember my e-mail address Forgot Password?

Not Registered?

1488804 11/11

Forgot Your Password?

Close

To receive an e-mail with your password, please enter the e-mail address you provided for this account.

 

Return to Login

 
1488804 11/11

Password Sent

Close

You will receive a temporary password shortly. Please check your e-mail and log in again.


Return to Login

1488804 11/11

Log In

Close

You have unsuccessfully attempted to log in 3 times. If you forgot your password, click here. If you forgot the e-mail address used to create your account, call 1-800-236-9933, Monday through Friday, 8 am to 6 pm ET, excluding holidays.


1488804 11/11

Please Log In to Access This Content

Close

Not Registered?

Some content on AZ TouchPoints is available to registered users only. Once registered, you can use your e-mail address and password to log into any Web site powered by AZ TouchPoints.


Log In

 
Remember me Forgot Password?

1488804 11/11

Forgot Your Password?

To receive an e-mail with your password, please enter the e-mail address you provided for this account.

 

Return to Login

1488804 11/11

AZ TouchPoints Web Sites

Close
1488804 11/11

How Can We Help You?

Close

If you would like information regarding products from AstraZeneca,
please call

1-800-236-9933

Monday through Friday, 8:00 am to 6:00 pm ET, excluding holidays.

1488805 11/11

Visit the Suite of AZ TouchPoints Web Sites

Close